Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.45 |
| ▸ | GDA | Q9Y2T3 | 3/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | XDH | P47989 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.33 |
| ▸ | DPYD | Q12882 | 1/20 | 0.33 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3423321 | 0.73 | MAPT (0.44) | MAPTADORA2BGDAACHEXDH | |
| SCHEMBL5006819 | 0.72 | XDH (0.42) | MAPTADORA2BGDAACHEXDH | |
| SCHEMBL932949 | 0.69 | MAPT (0.53) | MAPTADORA2BGDAACHEXDH | |
| SCHEMBL30728071 | 0.69 | MAPT (0.53) | MAPTADORA2BGDAACHEXDH | |
| Uric Acid SCHEMBL30269772 | 0.69 | MAPT (0.53) | MAPTADORA2BGDAACHEXDH | |
| Uric Acid SCHEMBL2786719 | 0.69 | MAPT (0.53) | MAPTADORA2BGDAACHEXDH | |
| SCHEMBL2837685 | 0.69 | MAPT (0.53) | MAPTADORA2BGDAACHEXDH | |
| SCHEMBL932609 | 0.69 | MAPT (0.53) | MAPTADORA2BGDAACHEXDH | |
| Uric Acid SCHEMBL28407297 | 0.69 | MAPT (0.53) | MAPTADORA2BGDAACHEXDH | |
| SCHEMBL29737686 | 0.69 | MAPT (0.53) | MAPTADORA2BGDAACHEXDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2465859-A1 | 8-Triazolylxanthine derivatives, processes for their production and their use as adenosine receptor antagonists | Life & Brain GmbH (DE) | 2012-06-20 | — | — | EP | claimed |
| WO-2012076974-A1 | 8-TRIAZOLYLXANTHINE DERIVATIVES, PROCESSES FOR THEIR PRODUCTION AND THEIR USE AS ADENOSINE RECEPTOR ANTAGONISTS | LIFE & BRAIN GMBH (DE) | 2012-06-14 | — | — | WO | claimed |
| EP-2097415-A1 | 8-ETHINYLXANTHINE DERIVATIVES AS SELECTIVE A2A RECEPTOR ANTAGONISTS | Schwarz Pharma AG (DE) | 2009-09-09 | — | — | EP | claimed |
| WO-2008077557-A1 | 8-ETHINYLXANTHINE DERIVATIVES AS SELECTIVE A2A RECEPTOR ANTAGONISTS | SCHWARZ PHARMA AG (DE) | 2008-07-03 | — | — | WO | claimed |
| US-20240002416-A1 | MRGPRX4 Agonists and Antagonists | RHEINISCHE-FRIEDRICH-WILHELMS-UNIVERSITAT BONN (DE) | 2024-01-04 | — | — | US | disclosed |
| EP-4229059-A1 | 3-SUBSTITUTED XANTHINE DERIVATIVES AS MRGPRX4 RECEPTOR MODULATORS | Rheinische Friedrich-Wilhelms-Universität Bonn (DE) | 2023-08-23 | — | — | EP | disclosed |
| WO-2022079245-A1 | 3-SUBSTITUTED XANTHINE DERIVATIVES AS MRGPRX4 RECEPTOR MODULATORS | RHEINISCHE-FRIEDRICH-WILHELMS-UNIVERSITÄT BONN (DE) | 2022-04-21 | — | — | WO | disclosed |
| WO-2016159746-A1 | NOVEL ETHYNYLXANTHINES, THEIR PREPARATION AND USE AS INHIBITORS OF MATRIX METALLOPROTEINASES AND ANGIOGENESIS | LATVIAN INSTITUTE OF ORGANIC SYNTHESIS (LV) | 2016-10-06 | — | — | WO | disclosed |
| WO-2016159745-A1 | ETHYNYLXANTHINES, PREPARATION AND USE FOR CANCER TREATMENT | LATVIAN INSTITUTE OF ORGANIC SYNTHESIS (LV) | 2016-10-06 | — | — | WO | disclosed |
| WO-2016159747-A1 | ETHYNYLXANTHINES, PREPARATION AND USE AS CALCIUM ION CHANNEL MODULATORS | LATVIAN INSTITUTE OF ORGANIC SYNTHESIS (LV) | 2016-10-06 | — | — | WO | disclosed |
| WO-2016159745-A1 | ETHYNYLXANTHINES, PREPARATION AND USE FOR CANCER TREATMENT | LATVIAN INSTITUTE OF ORGANIC SYNTHESIS (LV) | 2016-10-06 | — | — | WO | disclosed |
| WO-2016159746-A1 | NOVEL ETHYNYLXANTHINES, THEIR PREPARATION AND USE AS INHIBITORS OF MATRIX METALLOPROTEINASES AND ANGIOGENESIS | LATVIAN INSTITUTE OF ORGANIC SYNTHESIS (LV) | 2016-10-06 | — | — | WO | disclosed |
| WO-2012076974-A1 | 8-TRIAZOLYLXANTHINE DERIVATIVES, PROCESSES FOR THEIR PRODUCTION AND THEIR USE AS ADENOSINE RECEPTOR ANTAGONISTS | LIFE & BRAIN GMBH (DE) | 2012-06-14 | — | — | WO | disclosed |
| US-8044061-B2 | Parkinson's disease, catalepsy, dystonia, dyskinetic syndrome, restless legs syndrome, migraine, pain, dementia, neurodegenerative disorders, alcohol withdrawal and/or ischemic conditions such as e.g. stroke or cardiac ischemia. | UCB PHARMA GMBH (DE) | 2011-10-25 | — | — | US | disclosed |
| CN-101631788-A | 8-alkynyl xanthine and derivative | SANOL ARZNEI SCHWARZ GMBH | 2010-01-20 | — | — | CN | disclosed |
| EP-2097415-A1 | 8-ETHINYLXANTHINE DERIVATIVES AS SELECTIVE A2A RECEPTOR ANTAGONISTS | Schwarz Pharma AG (DE) | 2009-09-09 | — | — | EP | disclosed |
| US-20080221134-A1 | 8-ALKYNYLXANTHINES AND DERIVATIVES | RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAET BONN (DE) | 2008-09-11 | — | — | US | disclosed |
| WO-2008077557-A1 | 8-ETHINYLXANTHINE DERIVATIVES AS SELECTIVE A2A RECEPTOR ANTAGONISTS | SCHWARZ PHARMA AG (DE) | 2008-07-03 | — | — | WO | disclosed |
| EP-1939197-A1 | 8-ethinylxanthine derivatives as selective A2A receptor antagonists | SCHWARZ PHARMA AG (DE) | 2008-07-02 | — | — | EP | disclosed |
| EP-1939197-A1 | 8-ethinylxanthine derivatives as selective A2A receptor antagonists | SCHWARZ PHARMA AG (DE) | 2008-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240002416-A1 | MRGPRX4 Agonists and Antagonists | MRGPRX4, MRGPRX1, MRGPRX2 | MAPT 4456/4885ADORA2B 262/4885GDA 1475/4885 |
| US-20080221134-A1 | 8-ALKYNYLXANTHINES AND DERIVATIVES | SLC6A3, PARK7, SLC18A2 | MAPT 757/4885ADORA2B 279/4885GDA 374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.